| Study to Assess KN3835 in the Treatment of Flexible/Semi-Flexible Hammertoe (HMT) (NCT07759362) | Endo USA Inc., a Keenova Therapeutics Company | 2026-08-01 |
| A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA) (NCT06169319) | Endo USA Inc., a Keenova Therapeutics Company | 2024-01-03 |
| Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease) (NCT06151197) | Endo USA Inc., a Keenova Therapeutics Company | 2023-11-28 |
| Real-World Data Study to Understand Effectiveness of Treatments in Peyronie's Disease (NCT05873595) | Endo USA Inc., a Keenova Therapeutics Company | 2023-06-20 |
| Real-World Data Study to Understand Participant Treatment Outcomes for Dupuytren's Contracture (NCT05877066) | Endo USA Inc., a Keenova Therapeutics Company | 2023-06-14 |
| Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks (NCT05419505) | Endo USA Inc., a Keenova Therapeutics Company | 2022-06-15 |
| Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar Fibromatosis (NCT05254457) | Endo USA Inc., a Keenova Therapeutics Company | 2022-02-14 |
| Durability and Safety of CCH With Two Different Injection Techniques in Cellulite With Laxity (NCT05249257) | Endo USA Inc., a Keenova Therapeutics Company | 2022-01-25 |
| Efficacy, Safety, and Tolerability, of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis (NCT05152173) | Endo USA Inc., a Keenova Therapeutics Company | 2021-11-29 |
| Effects of Mitigation Treatments on Bruising of CCH-aaes Treatment of Buttock Cellulite (NCT04677712) | Endo USA Inc., a Keenova Therapeutics Company | 2020-12-28 |
| Long-term Follow-up Durability (Efficacy) Study of EN3835 for the Treatment of AC of the Shoulder (Frozen Shoulder) (NCT04680156) | Endo USA Inc., a Keenova Therapeutics Company | 2020-12-17 |
| CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection Techniques (NCT04580303) | Endo USA Inc., a Keenova Therapeutics Company | 2020-10-01 |
| Safety and Efficacy of EN3835 in Participants With Frozen Shoulder (NCT04496167) | Endo USA Inc., a Keenova Therapeutics Company | 2020-07-29 |
| A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism (NCT04456296) | Endo USA Inc., a Keenova Therapeutics Company | 2020-06-30 |
| Long-term Durability Study of Collagenase Clostridium Histolyticum (CCH) (NCT04381117) | Endo USA Inc., a Keenova Therapeutics Company | 2020-05-06 |
| Histopathology Following CCH Injection (NCT04236635) | Endo USA Inc., a Keenova Therapeutics Company | 2019-12-20 |
| Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult Women (NCT04209530) | Endo USA Inc., a Keenova Therapeutics Company | 2019-11-20 |
| Real World CCH Study in Adult Females With Cellulite (NCT04170296) | Endo USA Inc., a Keenova Therapeutics Company | 2019-11-01 |
| Safety and Pharmacokinetics of Vasopressin in Healthy Volunteers (NCT04093050) | Endo USA Inc., a Keenova Therapeutics Company | 2019-10-10 |
| Durability and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women (NCT03893890) | Endo USA Inc., a Keenova Therapeutics Company | 2019-03-28 |
| Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite) (NCT03632993) | Endo USA Inc., a Keenova Therapeutics Company | 2018-09-18 |
| Safety and Pharmacokinetics of a Single Dose of CCH (3.36 mg) in Subjects With EFP (NCT03675685) | Endo USA Inc., a Keenova Therapeutics Company | 2018-09-18 |
| Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite) (NCT03526549) | Endo USA Inc., a Keenova Therapeutics Company | 2018-04-26 |
| Effectiveness and Safety of EN3835 in the Treatment of Cellulite in Women (NCT03446781) | Endo USA Inc., a Keenova Therapeutics Company | 2018-02-08 |
| Effectiveness and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women (NCT03428750) | Endo USA Inc., a Keenova Therapeutics Company | 2018-02-05 |
| Safety and Effectiveness of EN3835 in the Treatment of EFP in Women (NCT03329989) | Endo USA Inc., a Keenova Therapeutics Company | 2017-11-17 |
| EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite) (NCT02942160) | Endo USA Inc., a Keenova Therapeutics Company | 2016-10-05 |
| Clinical Study to Evaluate the Effectiveness, Safety, and Tolerability of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects (NCT02687451) | Endo USA Inc., a Keenova Therapeutics Company | 2016-04-01 |
| EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite) (NCT02724644) | Endo USA Inc., a Keenova Therapeutics Company | 2016-02-01 |
| Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease (NCT02298829) | Endo USA Inc., a Keenova Therapeutics Company | 2014-11-01 |
| An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Treating Men With Peyronie's Disease (NCT02267460) | Endo USA Inc., a Keenova Therapeutics Company | 2014-10-01 |
| Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules (NCT02193828) | Endo USA Inc., a Keenova Therapeutics Company | 2014-07-01 |
| Clinical Study for the Treatment of Adhesive Capsulitis of the Shoulder (NCT02006719) | Endo USA Inc., a Keenova Therapeutics Company | 2013-11-01 |
| A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (NCT01987986) | Endo USA Inc., a Keenova Therapeutics Company | 2013-10-01 |
| Safety, Tolerability, Effectiveness, and Pharmacokinetic Data in Opioid-experienced Children (NCT04681027) | Endo USA Inc., a Keenova Therapeutics Company | 2013-03-11 |
| Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant (NCT01774435) | Endo USA Inc., a Keenova Therapeutics Company | 2012-10-01 |
| A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease (NCT01685437) | Endo USA Inc., a Keenova Therapeutics Company | 2012-09-01 |
| CORRECT: COmmunity RegistRy Study Evaluating Dupuytren's Contracture Treatment (NCT01715467) | Endo USA Inc., a Keenova Therapeutics Company | 2012-09-01 |
| Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures (NCT01674634) | Endo USA Inc., a Keenova Therapeutics Company | 2012-09-01 |
| Retreatment of Recurrent Dupuytren's Contractures (NCT01498640) | Endo USA Inc., a Keenova Therapeutics Company | 2012-03-01 |
| Post Approval Commitment Study (NCT01444729) | Endo USA Inc., a Keenova Therapeutics Company | 2012-03-01 |
| The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite) (NCT01518907) | Endo USA Inc., a Keenova Therapeutics Company | 2012-01-01 |
| AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder (NCT01483963) | Endo USA Inc., a Keenova Therapeutics Company | 2011-11-01 |
| Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease (NCT01430169) | Endo USA Inc., a Keenova Therapeutics Company | 2011-09-01 |
| Administration of Two Injections for Multiple Dupuytren's Contractures (NCT01407068) | Endo USA Inc., a Keenova Therapeutics Company | 2011-09-01 |
| A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC) (NCT01314664) | Endo USA Inc., a Keenova Therapeutics Company | 2011-05-01 |
| Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder (NCT01310803) | Endo USA Inc., a Keenova Therapeutics Company | 2011-05-01 |
| Retrospective Chart Review of Valstar (NCT01304173) | Endo USA Inc., a Keenova Therapeutics Company | 2011-03-01 |
| Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly (NCT01295060) | Endo USA Inc., a Keenova Therapeutics Company | 2011-02-01 |
| Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects (NCT01210352) | Endo USA Inc., a Keenova Therapeutics Company | 2010-12-13 |
| Time to Eugonadal Range, Time to Steady State and Drying Time (NCT01228071) | Endo USA Inc., a Keenova Therapeutics Company | 2010-11-01 |
| A Study of AA4500 in Men With Peyronie's Disease (NCT01243411) | Endo USA Inc., a Keenova Therapeutics Company | 2010-11-01 |
| Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects (NCT01206907) | Endo USA Inc., a Keenova Therapeutics Company | 2010-10-01 |
| Study of AA4500 in the Treatment of Peyronie's Disease (NCT01221623) | Endo USA Inc., a Keenova Therapeutics Company | 2010-10-01 |
| Study of AA4500 in the Treatment of Peyronie's Disease (NCT01221597) | Endo USA Inc., a Keenova Therapeutics Company | 2010-09-01 |
| Longterm Observational Study in Subjects Treated With AA4500 in AUX-CC-854, 856, 857, 858 & 859 (NCT00954746) | Endo USA Inc., a Keenova Therapeutics Company | 2009-07-01 |
| Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome (NCT00884715) | Endo USA Inc., a Keenova Therapeutics Company | 2009-07-01 |
| Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin) (NCT00955110) | Endo USA Inc., a Keenova Therapeutics Company | 2009-06-01 |
| Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects. (NCT00801398) | Endo USA Inc., a Keenova Therapeutics Company | 2009-02-17 |
| A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stuttering (NCT00830154) | Endo USA Inc., a Keenova Therapeutics Company | 2009-02-01 |
| Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects (NCT00765856) | Endo USA Inc., a Keenova Therapeutics Company | 2008-11-17 |
| Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly (NCT00765323) | Endo USA Inc., a Keenova Therapeutics Company | 2008-09-01 |
| The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease (NCT00755222) | Endo USA Inc., a Keenova Therapeutics Company | 2008-08-01 |
| AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease (NCT00528424) | Endo USA Inc., a Keenova Therapeutics Company | 2007-12-01 |
| EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer (NCT00574860) | Endo USA Inc., a Keenova Therapeutics Company | 2007-12-01 |
| Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease (NCT00528840) | Endo USA Inc., a Keenova Therapeutics Company | 2007-10-01 |
| A Pharmacokinetic Study of AA4500 (XIAFLEX™, Proposed Name) in Subjects With Dupuytren's Contracture (NCT00528931) | Endo USA Inc., a Keenova Therapeutics Company | 2007-09-01 |
| Non-US Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease (NCT00533273) | Endo USA Inc., a Keenova Therapeutics Company | 2007-08-01 |
| A Study of Fortigel Testosterone Gel 2% in Males With Low Testosterone (NCT00522431) | Endo USA Inc., a Keenova Therapeutics Company | 2007-08-01 |
| AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture (NCT00528606) | Endo USA Inc., a Keenova Therapeutics Company | 2007-08-01 |
| Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease (NCT00465959) | Endo USA Inc., a Keenova Therapeutics Company | 2007-04-01 |
| Efficacy and Safety of the Lidoderm Patch Applied to Patients With Osteoarthritis of the Knee (NCT00589979) | Endo USA Inc., a Keenova Therapeutics Company | 2007-03-01 |
| Open Label Study of Octreotide Implant in Patients With Acromegaly (NCT00913055) | Endo USA Inc., a Keenova Therapeutics Company | 2007-02-01 |
| Exploratory Study of Pagoclone in Men With Premature Ejaculation. (NCT00370981) | Endo USA Inc., a Keenova Therapeutics Company | 2006-07-01 |
| Vantas Implant Retrieval Study (NCT01013025) | Endo USA Inc., a Keenova Therapeutics Company | 2006-07-01 |
| Evaluating the Effect of Food on Absorption of Megace ES (NCT00638079) | Endo USA Inc., a Keenova Therapeutics Company | 2006-06-01 |
| Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men (NCT00467870) | Endo USA Inc., a Keenova Therapeutics Company | 2006-03-01 |
| Safety and Efficacy of Lidoderm (Lidocaine Patch 5%) in Treating Moderate to Severe Pain Associated With Carpal Tunnel Syndrome (NCT00266214) | Endo USA Inc., a Keenova Therapeutics Company | 2005-11-01 |
| Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection (NCT00262106) | Endo USA Inc., a Keenova Therapeutics Company | 2005-10-01 |
| Effectiveness And Safety Of Frovatriptan For The Management (Acute Treatment) Of Menstrual Migraine (NCT00904098) | Endo USA Inc., a Keenova Therapeutics Company | 2005-09-01 |
| EXPRESS: Examining Pagoclone for Persistent Developmental Stuttering Study (NCT00216255) | Endo USA Inc., a Keenova Therapeutics Company | 2005-04-01 |
| Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss (NCT00637572) | Endo USA Inc., a Keenova Therapeutics Company | 2004-12-01 |
| Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain (NCT00225797) | Endo USA Inc., a Keenova Therapeutics Company | 2004-11-01 |
| Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain (NCT00226421) | Endo USA Inc., a Keenova Therapeutics Company | 2004-10-01 |
| A Controlled Trial to Investigate the Efficacy and Safety of Frovatriptan to Prevent Menstrual Migraine (NCT00475514) | Endo USA Inc., a Keenova Therapeutics Company | 2004-10-01 |
| Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain (NCT00226395) | Endo USA Inc., a Keenova Therapeutics Company | 2004-09-01 |
| Histrelin Subcutaneous Implant in Children With Central Precocious Puberty (NCT00779103) | Endo USA Inc., a Keenova Therapeutics Company | 2004-09-01 |
| Pilot Study of Lidocaine 5% Patch Versus Placebo in Patients With Osteoarthritis Pain of the Knee (NCT00904462) | Endo USA Inc., a Keenova Therapeutics Company | 2004-08-01 |
| A Study Comparing The Efficacy And Safety Of Lidocaine 5% Patch With Placebo In Patients With Chronic Axial Low Back Pain (NCT00904111) | Endo USA Inc., a Keenova Therapeutics Company | 2004-08-01 |
| Lidocaine Patch 5% Versus Celecoxib 200 mg in Chronic Axial Low Back Pain (NCT00904397) | Endo USA Inc., a Keenova Therapeutics Company | 2004-07-01 |
| Lidocaine Patch Versus Celecoxib in Pain From Osteoarthritis of the Knee (NCT00904605) | Endo USA Inc., a Keenova Therapeutics Company | 2004-06-01 |
| Safety and Tolerability of Frovatriptan to Prevention of Menstrually Associated Migraine (MAM) Headaches (NCT01035983) | Endo USA Inc., a Keenova Therapeutics Company | 2003-12-01 |
| Oxymorphone Extended Release in Patients With Cancer or Neuropathic Pain (NCT00911261) | Endo USA Inc., a Keenova Therapeutics Company | 2003-08-01 |
| Oxymorphone Extended Release (ER) in Opioid-Naive Patients With Chronic Pain (NCT00911287) | Endo USA Inc., a Keenova Therapeutics Company | 2003-06-01 |
| Post-operative Efficacy and Safety Study (NCT00904085) | Endo USA Inc., a Keenova Therapeutics Company | 2003-04-01 |
| Pilot Study of the Efficacy and Safety of Lidoderm Patch in the Treatment of Low Back Pain (NCT00904475) | Endo USA Inc., a Keenova Therapeutics Company | 2003-04-01 |
| A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions (NCT00904202) | Endo USA Inc., a Keenova Therapeutics Company | 2003-01-01 |
| A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain (NCT00904020) | Endo USA Inc., a Keenova Therapeutics Company | 2002-06-01 |
| Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy (NCT00903851) | Endo USA Inc., a Keenova Therapeutics Company | 2002-04-01 |
| Topical Lidocaine Patch in Low Back Pain (NCT00904540) | Endo USA Inc., a Keenova Therapeutics Company | 2002-03-01 |